do not combine dpp-4 inhibitors with glp-1 receptor agonists guidance It's the first in a class of drugs called Frontiers | Mechanisms of action
Description
Glp1r / mice exhibited exacerbated intestinal inflammation in a dextran sulfate sodiuminduced model of colitis (33)

J., Rosenstock, J., Manghi, F

You can also report suspected side effects directly via the Yellow Card scheme at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store

A meta-analysis of 4 RCTs confirmed the safety profile was comparable to control and that retatrutide was clinically and statistically superior to placebo on all primary weight loss endpoints

Endocrinology (2011) 152:40729
But until now, there hasnt been any data from large epidemiologic studies. Results showed use of GLP-1 agonists compared with bupropion-naltrexone correlated with a 9.09 (95% CI, 1.25-66), 4.22 (95% CI, 1.02-17.4) and 3.67 (95% CI, 1.15-11.9) times higher risk for pancreatitis, bowel obstruction and gastroparesis, respectively
